Aurinia Pharmaceuticals Reports Strong Q4 and Full-Year 2025 Key Points:
Earnings Date: Results reported on February 26, 2026, for periods ending December 31, 2025.
Total Revenue: Q4: $77.1M (+29% YoY); Full Year: $283.1M (+20% YoY).
LUPKYNIS Sales: Q4: $74.2M (+29% YoY); Full Year: $271.3M (+25% YoY).
Balance Sheet: Cash and investments of $398.0M (up from $358.5M in 2024).
Capital Return: Repurchased 12.2M shares for $98.2M in 2025.
2026 Guidance: Total revenue $315M-$325M (+11-15%); LUPKYNIS sales $305M-$315M (+12-16%).
The Full Story:
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH), a clinical-stage biopharmaceutical company focused on the research, development, and commercialization of therapeutic drugs, announced its financial results for the three and twelve months ended December 31, 2025, on February 26, 2026. The report painted a picture of a company in a strong growth phase, driven entirely by the performance of its flagship asset, LUPKYNIS.
Robust Revenue Growth Driven by LUPKYNIS
Total revenue for the fourth quarter of 2025 reached $77.1 million, a substantial 29% increase compared to the $59.9 million reported in the fourth quarter of 2024. For the full year, total revenue climbed to $283.1 million, up 20% from the $235.1 million recorded in the prior year. This top-line expansion was fueled by continued strong demand for LUPKYNIS, the first FDA-approved oral therapy indicated for the treatment of adult patients with active lupus nephritis.
Net product sales of LUPKYNIS mirrored this growth trajectory. In the fourth quarter, sales hit $74.2 million, representing a 29% year-over-year increase from $57.6 million. For the entirety of 2025, LUPKYNIS generated $271.3 million in net sales, a robust 25% improvement over the $216.2 million reported for 2024. These figures underscore the drug's successful market penetration and its status as a key therapeutic option for a debilitating autoimmune condition.
Strengthened Balance Sheet and Shareholder Returns
Aurinia also reported a healthier financial position at the close of 2025. The company held cash, cash equivalents, restricted cash, and investments totaling $398.0 million, up from $358.5 million at the end of 2024. This increase in liquidity provides a solid foundation for ongoing operations and potential future investments.
Demonstrating confidence in its business and a commitment to returning value to shareholders, Aurinia actively repurchased 12.2 million of its common shares during 2025. The total cost of these repurchases amounted to $98.2 million, reflecting an opportunistic approach to capital allocation.
A Cautiously Optimistic Outlook for 2026
Looking forward, Aurinia provided guidance for the full year 2026 that anticipates continued growth, albeit at a more measured pace as the LUPKYNIS franchise matures. The company expects total revenue for the year to be in the range of $315 million to $325 million. If achieved, this would represent an 11% to 15% increase over the $283.1 million reported for 2025. Within this total, net product sales of LUPKYNIS are projected to contribute between $305 million and $315 million, translating to a projected year-over-year growth rate of 12% to 16% when compared to the $271.3 million recorded in 2025. This guidance suggests management's confidence in the continued strength of its core product while acknowledging the natural deceleration that comes with a maturing commercial-stage asset.
Long
